Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Breast Neoplasms 15Prostatic Neoplasms 10Neoplasms 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Leukemia, Myeloid, Acute 4Triple Negative Breast Neoplasms 3Ovarian Neoplasms 3Myelodysplastic Syndromes 3Endometrial Neoplasms 3Colorectal Neoplasms 3Colonic Neoplasms 3Cardiovascular Diseases 3Cardiotoxicity 3Rectal Neoplasms 2Polycystic Ovary Syndrome 2Pancreatic Neoplasms 2Neoplasm Metastasis 2Melanoma 2Lymphoma, Non-Hodgkin 2Leukemia 2Kidney Neoplasms 2Heart Failure 2Head and Neck Neoplasms 2Glioblastoma 2Endometrial Hyperplasia 2Carcinoma, Renal Cell 2Waldenstrom Macroglobulinemia 1Venous Thrombosis 1Urogenital Neoplasms 1Smoking 1

Interventions

sacubitril and valsartan sodium hydrate drug combination 3Nutrition Assessment 3Exercise 3Carvedilol 3dapagliflozin 2Standard of Care 2Rituximab 2Ivabradine 2Control Groups 2Atorvastatin 2pertuzumab 1pegfilgrastim 1obinutuzumab 1nicotinamide-beta-riboside 1empagliflozin 1candesartan 1acalabrutinib 1Vincristine 1Valsartan 1Trastuzumab 1Surveys and Questionnaires 1Spironolactone 1Sodium Chloride 1Simendan 1Secondary Prevention 1Resistance Training 1Pyruvic Acid 1Prednisolone 1Practice Guidelines as Topic 1Population Groups 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Heart Failure × Atorvastatin × Clear all
NCT02943590 2025-05-15

STOP-CA (Statins TO Prevent the Cardiotoxicity From Anthracyclines)

Massachusetts General Hospital

Phase 2 Completed
300 enrolled 13 charts

Heart Failure

NCT03186404 2022-02-08

SPARE-HF

University Health Network, Toronto

Phase 2 Unknown
112 enrolled

Heart Failure, Neoplasms, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡